CA2359681A1 - Method of treating chronic cardiac disease - Google Patents

Method of treating chronic cardiac disease Download PDF

Info

Publication number
CA2359681A1
CA2359681A1 CA002359681A CA2359681A CA2359681A1 CA 2359681 A1 CA2359681 A1 CA 2359681A1 CA 002359681 A CA002359681 A CA 002359681A CA 2359681 A CA2359681 A CA 2359681A CA 2359681 A1 CA2359681 A1 CA 2359681A1
Authority
CA
Canada
Prior art keywords
cardiac disease
bpi
leu
ser
chronic cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002359681A
Other languages
English (en)
French (fr)
Inventor
Brett P. Giroir
Patrick J. Scannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Xoma Technology Ltd USA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2359681A1 publication Critical patent/CA2359681A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002359681A 1999-01-22 2000-01-21 Method of treating chronic cardiac disease Abandoned CA2359681A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11673699P 1999-01-22 1999-01-22
US60/116,736 1999-01-22
PCT/US2000/001515 WO2000043028A2 (en) 1999-01-22 2000-01-21 Method of treating chronic cardiac disease

Publications (1)

Publication Number Publication Date
CA2359681A1 true CA2359681A1 (en) 2000-07-27

Family

ID=22368911

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002359681A Abandoned CA2359681A1 (en) 1999-01-22 2000-01-21 Method of treating chronic cardiac disease

Country Status (11)

Country Link
US (3) US6509317B1 (enExample)
EP (1) EP1143996B1 (enExample)
JP (2) JP2002535282A (enExample)
CN (1) CN1353614A (enExample)
AT (1) ATE239492T1 (enExample)
AU (1) AU778001B2 (enExample)
CA (1) CA2359681A1 (enExample)
DE (1) DE60002552T2 (enExample)
MX (1) MXPA01007031A (enExample)
NZ (1) NZ513087A (enExample)
WO (1) WO2000043028A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339424A2 (en) 2000-12-01 2003-09-03 XOMA Technology Ltd. Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
WO2010062738A1 (en) * 2008-11-03 2010-06-03 Ut-Battelle, Llc Diagnosis and treatment of congenital heart defects using nell 1
US9974759B2 (en) * 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643875A (en) 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5578568A (en) 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
DK0914144T3 (da) * 1996-05-10 2001-04-09 Univ Texas Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi

Also Published As

Publication number Publication date
JP2002535282A (ja) 2002-10-22
US6509317B1 (en) 2003-01-21
AU2734100A (en) 2000-08-07
DE60002552D1 (de) 2003-06-12
DE60002552T2 (de) 2004-02-26
EP1143996A2 (en) 2001-10-17
EP1143996A4 (de) 2002-04-24
US20030216312A1 (en) 2003-11-20
CN1353614A (zh) 2002-06-12
WO2000043028A9 (en) 2001-09-20
JP2007126479A (ja) 2007-05-24
AU778001B2 (en) 2004-11-11
US20060171937A1 (en) 2006-08-03
ATE239492T1 (de) 2003-05-15
MXPA01007031A (es) 2004-08-12
WO2000043028A2 (en) 2000-07-27
EP1143996B1 (en) 2003-05-07
NZ513087A (en) 2003-02-28
WO2000043028A3 (en) 2000-11-30
US7045501B2 (en) 2006-05-16

Similar Documents

Publication Publication Date Title
US5990086A (en) Therapeutic uses of BPI protein products for human meningococcemia
US5912228A (en) Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US20020090368A1 (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5945399A (en) Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
JP2007126479A (ja) 慢性心臓疾患を処置する方法
WO1998019694A1 (en) Therapeutic uses of bpi protein products in cystic fibrosis patients
CA2367943A1 (en) Therapeutic uses of bpi protein products in bpi-deficient humans
US6482796B2 (en) Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US20030194377A1 (en) Therapeutic uses of BPI protein products in cystic fibrosis patients
US20030027762A1 (en) Therapeutic uses of BPI protein products in BPI-deficient humans
Scannon Therapeutic uses of BPI protein products for human meningococcemia
HK1019856B (en) Therapeutic uses of bpi protein products for human meningococcemia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued